|
Oct 2
|
Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas
|
|
Sep 27
|
New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma
|
|
Sep 23
|
New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett’s Esophagus
|
|
Sep 16
|
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
|
|
Jul 29
|
Will Castle Biosciences, Inc. (CSTL) Report Negative Earnings Next Week? What You Should Know
|
|
Jul 25
|
Investors in Castle Biosciences (NASDAQ:CSTL) have unfortunately lost 71% over the last three years
|
|
Jul 19
|
5 Top Small Cap Stocks to Buy Now
|
|
Jul 15
|
Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024
|
|
Jun 24
|
Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher® Test
|
|
Jun 14
|
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner
|
|
Jun 13
|
Is Castle Biosciences (CSTL) Outperforming Other Medical Stocks This Year?
|
|
May 29
|
New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis
|
|
May 23
|
Does Castle Biosciences (CSTL) Have the Potential to Rally 36.15% as Wall Street Analysts Expect?
|
|
May 23
|
What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing'
|
|
May 15
|
Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference
|
|
May 14
|
Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024
|
|
May 10
|
Castle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for "Best Overall Mental Health Solution"
|
|
May 8
|
Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result
|
|
May 7
|
Wall Street Analysts Predict a 36.09% Upside in Castle Biosciences (CSTL): Here's What You Should Know
|
|
May 6
|
Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable
|